Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for AZTA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -50.32M
March 31, 2026 0.98M
December 31, 2025 -2.632M
September 30, 2025 0.817M
June 30, 2025 -0.128M
March 31, 2025 -5.154M
December 31, 2024 -5.126M
September 30, 2024 -247.55M
June 30, 2024 -226.12M
March 31, 2024 -72.39M
December 31, 2023 -113.15M
September 30, 2023 -166.86M
June 30, 2023 -172.08M
March 31, 2023 -0.416M
December 31, 2022 -504.72M
September 30, 2022 1.751M
June 30, 2022 -1.043M
March 31, 2022 -55.79M
December 31, 2021 -7.68M
September 30, 2021 -4.458M
June 30, 2021 -8.123M
March 31, 2021 -5.168M
December 31, 2020 -8.157M
September 30, 2020 -5.443M
June 30, 2020 -8.11M
Date Value
March 31, 2020 -5.368M
December 31, 2019 -8.102M
September 30, 2019 -500.96M
June 30, 2019 -10.24M
March 31, 2019 -11.38M
December 31, 2018 331.42M
September 30, 2018 -6.152M
June 30, 2018 -7.577M
March 31, 2018 -6.173M
December 31, 2017 190.18M
September 30, 2017 -5.921M
June 30, 2017 -6.987M
March 31, 2017 -6.019M
December 31, 2016 -6.993M
September 30, 2016 -5.784M
June 30, 2016 -7.383M
March 31, 2016 -5.946M
December 31, 2015 -6.844M
September 30, 2015 -14.28M
June 30, 2015 -6.873M
March 31, 2015 -6.005M
December 31, 2014 -6.852M
September 30, 2014 -9.288M
June 30, 2014 -5.344M
March 31, 2014 -4.442M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Agilent Technologies, Inc. 471.00M
Bio-Rad Laboratories, Inc. -27.60M
Bruker Corp. 149.20M
Danaher Corp. 7.273B
Harvard Bioscience, Inc. -0.036M